Author Type

Graduate Student

Date of Award

2018

Document Type

Thesis

Publication Status

Version of Record

Submission Date

October 2026

Thesis/Dissertation Advisor [Chair]

Pella, Silvia

Thesis/Dissertation Co-Chair

Leventouri, Theodora

Abstract

Intracavitary high-dose-rate brachytherapy (HDRBT) is a treatment option for endometrial cancer, depending on the cancer stage. Because of the steep high dose gradient of HDRBT, very small differences in the treatment plans, surrounding organ’s anatomy, or procedures during the treatment could potentially cause significant dose variation to the tumor, as well as organs at risks (OAR) nearby the treatment area, which could result in unwanted radiobiological side effects. In this retrospective study, the radiobiological plan evaluation parameters Equivalent Uniform Dose (EUD), Normal Tissue Complication Probability (NTCP) are used as assessment tools to evaluate HDRBT plans. Furthermore, gynecological applicator position in the coordinate system, and possible dose variations to the tumor and critical organs from the initial fraction in comparison with subsequent fractions over the entire multi fractionated treatment are studied. The evaluations were performed for 118 HDR treatment plans for 30 patients by registration of the subsequent treatment plans into the initial CT-image guided plan. Dose fractionation regimens varied from 4Gy to 7Gy per fraction, 1 or 2 fractions per week, depending on the cancer stage. Our results demonstrate no significant radiobiological impacts on organs at risks (OAR). In addition, the results of the applicator positions’ study indicate that improvement of immobilization and localization devices are recommended.

Extent

61 p.

Comments

Includes bibliography.|Thesis (M.S.)--Florida Atlantic University, 2018.|FAU Electronic Theses and Dissertations Collection|Includes bibliography.

Identifier

FA00013144

Format

pdf

Download

Share

COinS